Replies to post #6775 on Celsion Corporation (CLSN)

[Rawnoc]

YOU were taking management's words and misunderstanding them. When I corrected you, and explained that management's words were for only one indication, suddenly you want to now stop using management's own words and demand I provide some additional evidence?

I have actually posted a myriad of other evidence on this board before. You can Google it -- there's been dozens of studies that show it's less than 12 months for both indications.

As for your link, that's for overall RFA-only including small tumors. It's already widely known by everybody on this board that RFA-only is effectively against small tumors with an extremely high success rate. What we, and CLSN management, are rerferring to is statistics for LARGE tumors. You made the same silly argument Adam F made. You're both dead wrong.

[Rawnoc]

Try reading your own link. Page 8:

"RFA for Large HCC > 5 cm
•Percutaneous RFA for HCC > 5 cm:
Complete ablation rate < 50%
(compared with 90% for HCC < 3 cm)"

Large (and local only!) = less than 50%
Small = 90%

[Rawnoc]

By the way, the stats get EVEN WORSE across the board for CLSN's HEAT trial....

Because even those local recurrence stats are PER TUMOR and the HEAT patients have up to FOUR tumors.

So a patient with two large tumors has a 50% chance of local recurrence EACH tumor by 12 months or 75% local recurrence alone! The fact that so few people had any recurrence vs. what should have happened is proof that TDOX works.

[gold team]

please,
what will data say ?
when will we get date ?
please keep it simple.
thanks